Journal Home Online First Current Issue Archive For Authors Journal Information 中文版

Frontiers of Medicine >> 2017, Volume 11, Issue 4 doi: 10.1007/s11684-017-0602-z

Universal influenza virus vaccines: what can we learn from the human immune response following exposure to H7 subtype viruses?

1. Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10024, USA.

2. Department of Biotechnology, University of Natural Resources and Life Sciences, 1190, Vienna, Austria.

3. Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10024, USA

Available online: 2017-12-04

Next Previous

Abstract

Several universal influenza virus vaccine candidates based on eliciting antibodies against the hemagglutinin stalk domain are in development. Typically, these vaccines induce responses that target group 1 or group 2 hemagglutinins with little to no cross-group reactivity and protection. Similarly, the majority of human anti-stalk monoclonal antibodies that have been isolated are directed against group 1 or group 2 hemagglutinins with very few that bind to hemagglutinins of both groups. Here we review what is known about the human humoral immune response to vaccination and infection with H7 subtype influenza viruses on a polyclonal and monoclonal level. It seems that unlike vaccination with H5 hemagglutinin, which induces antibody responses mostly restricted to the group 1 stalk domain, H7 exposure induces both group 2 and cross-group antibody responses. A better understanding of this phenomenon and the underlying mechanisms might help to develop future universal influenza virus vaccine candidates.

Related Research